Related Experiment Video
Updated: Nov 20, 2025
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
Published on: November 17, 2018
Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
Wenjie Gong1,2, Lei Wang1, Sophia Stock1
1Department of Internal Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Abstract:
NY-ESO-1-specific T cells have shown promising activity in the treatment of soft tissue sarcoma (STS). However, standardized protocols for their generation are limited. Particularly, cost-effectiveness considerations of cell production protocols are of importance for conducting clinical studies. In this study, two different NY-ESO-1-specific T cell production protocols were compared. Major differences between protocols 1 and 2 include culture medium, interleukin-2 and retronectin concentrations, T cell activation strategy, and the transduction process. NY-ESO-1-specific T cells generated according to the two protocols were investigated for differences in cell viability, transduction efficiency, T cell expansion, immunophenotype as well as functionality. NY-ESO-1-specific T cells showed similar viability and transduction efficiency between both protocols. Protocol 1 generated higher absolute numbers of NY-ESO-1-specific T cells. However, there was no difference in absolute numbers of NY-ESO-1-specific T cell subsets with less-differentiated phenotypes accounting for efficient in vivo expansion and engraftment. Furthermore, cells generated according to protocol 1 displayed higher capacity of TNF-α generation, but lower cytotoxic capacities. Overall, both protocols provided functional NY-ESO-1-specific T cells. However, compared to protocol 1, protocol 2 is advantageous in terms of cost-effectiveness. Cell production protocols should be designed diligently to achieve a cost-effective cellular product for further clinical evaluation.
Insights
Comparing two NY-ESO-1 specific T cell production protocols for soft tissue sarcoma (STS) treatment, protocol 2 offers a cost-effective approach while maintaining cellular function for clinical studies.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- NY-ESO-1 specific T cells show promise for soft tissue sarcoma (STS) treatment.
- Standardized and cost-effective T cell generation protocols are needed for clinical application.
Purpose of the Study:
- To compare two distinct NY-ESO-1 specific T cell production protocols.
- To evaluate differences in cell viability, expansion, immunophenotype, and functionality.
- To determine the cost-effectiveness of each protocol for clinical studies.
Main Methods:
- Two NY-ESO-1 specific T cell production protocols (Protocol 1 and Protocol 2) were utilized.
- Key differences included culture medium, cytokine concentrations, activation strategy, and transduction methods.
- Generated T cells were analyzed for viability, transduction efficiency, expansion, immunophenotype, and functionality (TNF-α production, cytotoxicity).
Main Results:
- Both protocols yielded NY-ESO-1 specific T cells with similar viability and transduction efficiency.
- Protocol 1 produced higher absolute numbers of T cells, but no significant difference in less-differentiated subsets.
- Protocol 1 showed enhanced TNF-α production but reduced cytotoxic capacity; Protocol 2 was more cost-effective.
Conclusions:
- Both protocols generate functional NY-ESO-1 specific T cells for soft tissue sarcoma treatment.
- Protocol 2 presents a more cost-effective option for clinical evaluation.
- Careful design of cell production protocols is crucial for developing cost-effective cellular therapies.
More Related Videos
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
13:41Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012